UY24989A1 - CARPROPHEN, A COX-2 INHIBITOR, USEFUL IN TREATING PAIN AND INFLAMMATION IN DOGS - Google Patents

CARPROPHEN, A COX-2 INHIBITOR, USEFUL IN TREATING PAIN AND INFLAMMATION IN DOGS

Info

Publication number
UY24989A1
UY24989A1 UY24989A UY24989A UY24989A1 UY 24989 A1 UY24989 A1 UY 24989A1 UY 24989 A UY24989 A UY 24989A UY 24989 A UY24989 A UY 24989A UY 24989 A1 UY24989 A1 UY 24989A1
Authority
UY
Uruguay
Prior art keywords
cox
inhibitor
activity
dogs
carprophen
Prior art date
Application number
UY24989A
Other languages
Spanish (es)
Inventor
Ricketts Anthony Paul
Lundy Kristin Marie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY24989A1 publication Critical patent/UY24989A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Tratamiento o prevención de procesos y enfermedades inflamatorias en perros asociadas con la actividad de la ciclo-oxigenasa-2 (COX-2) inducible, mientras que al mismo tiempo se reducen o eliminan los efectos secundarios indeseables asociados con la inhibición simultánea de la actividad de la ciclo-oxigenasa-1 (COX-1) constitutiva, mediante la inhibición selectiva de la actividad de COX-2 con respecto a la actividad de la COX-1, donde la relación de selectividad de COX-2:COX-1 es de al menos 3:1 basándose en los niveles de inhibición ex vivo medidos en sangre entera; el inhibidor es un miembro seleccionado entre el grupo de AINEs (anti-inflamatorios no esteroideos). En particular, el inhibidor de COX-2 que se reinvidica es el carprofeno [(+)-(S) ácido 6-cloro-alfa-metil-9H-carbazol-2-acético].Treatment or prevention of inflammatory processes and diseases in dogs associated with inducible cyclooxygenase-2 (COX-2) activity, while at the same time reducing or eliminating undesirable side effects associated with the simultaneous inhibition of the activity of constitutive cyclooxygenase-1 (COX-1), by selective inhibition of COX-2 activity relative to COX-1 activity, where the selectivity ratio of COX-2: COX-1 is at least 3: 1 based on ex vivo levels of inhibition measured in whole blood; the inhibitor is a member selected from the group of NSAIDs (non-steroidal anti-inflammatory drugs). In particular, the reinvoked COX-2 inhibitor is carprofen [(+) - (S) 6-chloro-alpha-methyl-9H-carbazol-2-acetic acid].

UY24989A 1997-05-05 1998-05-04 CARPROPHEN, A COX-2 INHIBITOR, USEFUL IN TREATING PAIN AND INFLAMMATION IN DOGS UY24989A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4563597P 1997-05-05 1997-05-05

Publications (1)

Publication Number Publication Date
UY24989A1 true UY24989A1 (en) 2001-10-25

Family

ID=21939053

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24989A UY24989A1 (en) 1997-05-05 1998-05-04 CARPROPHEN, A COX-2 INHIBITOR, USEFUL IN TREATING PAIN AND INFLAMMATION IN DOGS

Country Status (32)

Country Link
EP (1) EP0988034A1 (en)
JP (1) JP2000513020A (en)
KR (2) KR20010012300A (en)
CN (1) CN1255059A (en)
AP (1) AP9801234A0 (en)
AR (2) AR011726A1 (en)
AU (1) AU6932198A (en)
BG (1) BG103852A (en)
BR (1) BR9808720A (en)
CA (1) CA2288759A1 (en)
DZ (1) DZ2479A1 (en)
EA (1) EA003696B1 (en)
GT (1) GT199800063A (en)
HR (1) HRP980244A2 (en)
HU (1) HUP0001286A3 (en)
ID (1) ID21311A (en)
IL (1) IL132570A0 (en)
IS (1) IS5220A (en)
MA (1) MA26491A1 (en)
NO (1) NO995389L (en)
NZ (1) NZ500183A (en)
OA (1) OA11213A (en)
PA (1) PA8450601A1 (en)
PE (1) PE72599A1 (en)
PL (1) PL337003A1 (en)
SK (1) SK148199A3 (en)
TN (1) TNSN98059A1 (en)
TW (1) TW590773B (en)
UY (1) UY24989A1 (en)
WO (1) WO1998050033A1 (en)
YU (1) YU55899A (en)
ZA (1) ZA983722B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
AU2003204888B2 (en) * 1998-05-22 2005-07-28 Pfizer Products Inc. Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives
US6506785B2 (en) * 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
CA2347365A1 (en) * 1998-10-23 2000-05-04 Merck Frosst Canada & Co. Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
DE60023119T2 (en) * 1999-03-10 2006-07-20 G.D. Searle Llc COMPOSITIONS FOR THE ADMINISTRATION OF A CYCLOOXYGENASE-2 HEMMER TO ANIMALS
WO2001034204A1 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001087343A2 (en) * 2000-05-15 2001-11-22 Merck Frosst Canada & Co. Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
PL206268B1 (en) 2000-06-13 2010-07-30 Wyethwyeth Analgesic and anti-inflammatory compositions containing cox-2 inhibitors
DE10032132A1 (en) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermal therapeutic system containing non-steroidal anti-inflammatory drugs with selective COX-2 inhibition
EP1307585B1 (en) 2000-08-07 2009-01-21 Vanderbilt University Compositions and methods for detecting and quantifying cox-2 activity and 2-arachidonylglycerol metabolites
WO2003007875A2 (en) * 2001-07-16 2003-01-30 Hoegestaett Edward Compounds with analgesic, antipyretic and/or anti-inflammatory activity
ES2275218T3 (en) 2003-05-07 2007-06-01 Osteologix A/S HYDROSOLUBLE STRONTIUM SALTS FOR THE TREATMENT OF CARTILAGOS AND / OR BONE AFFECTIONS.
MXPA06001288A (en) * 2003-07-31 2006-04-11 Upjohn Co Dispersible formulation of an anti-inflammatory agent.
EA200702280A1 (en) * 2005-05-20 2008-04-28 Пфайзер Лимитед SYNERGISTIC COMBINATIONS
JP2010523554A (en) 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド Pharmaceutical composition of tacrolimus
US8951570B2 (en) 2007-04-26 2015-02-10 Sigmoid Pharma Limited Manufacture of multiple minicapsules
GB2483815B (en) 2009-05-18 2013-12-25 Sigmoid Pharma Ltd Composition comprising oil drops
CN107582526A (en) 2009-08-12 2018-01-16 希格默伊德药业有限公司 Immune regulation composite comprising polymer substrate and oil phase
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CN105939713A (en) 2014-03-06 2016-09-14 阿莱塔纳治疗学股份有限公司 Compositions of grapiprant and methods for using same
AU2015341695B2 (en) 2014-11-07 2021-07-08 Sublimity Therapeutics Limited Compositions comprising cyclosporin
WO2016112312A1 (en) * 2015-01-09 2016-07-14 Jaguar Animal Health Methods of treating diarrhea in companion animals
WO2021195346A1 (en) * 2020-03-25 2021-09-30 Sri International Lipoxygenase inhibitors
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (en) 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 Pharmaceutical composition for preventing or treating keloid or hypertrophic scar comprising Benzbromarone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896145A (en) * 1972-07-24 1975-07-22 Hoffmann La Roche Carbazoles
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions

Also Published As

Publication number Publication date
HUP0001286A2 (en) 2000-11-28
GT199800063A (en) 1999-10-26
CA2288759A1 (en) 1998-11-12
WO1998050033A1 (en) 1998-11-12
PL337003A1 (en) 2000-07-31
EA199900895A1 (en) 2000-06-26
NZ500183A (en) 2002-04-26
ZA983722B (en) 1999-11-04
KR20010012300A (en) 2001-02-15
DZ2479A1 (en) 2003-02-01
AR011726A1 (en) 2000-08-30
AP9801234A0 (en) 1999-11-04
PE72599A1 (en) 1999-08-12
PA8450601A1 (en) 2000-05-24
MA26491A1 (en) 2004-12-20
NO995389D0 (en) 1999-11-04
EA003696B1 (en) 2003-08-28
OA11213A (en) 2003-07-14
SK148199A3 (en) 2001-09-11
IS5220A (en) 1999-10-19
AR039628A2 (en) 2005-03-02
YU55899A (en) 2003-08-29
KR20040004406A (en) 2004-01-13
AU6932198A (en) 1998-11-27
HUP0001286A3 (en) 2000-12-28
CN1255059A (en) 2000-05-31
TW590773B (en) 2004-06-11
EP0988034A1 (en) 2000-03-29
NO995389L (en) 2000-01-04
ID21311A (en) 1999-05-20
HRP980244A2 (en) 1999-02-28
JP2000513020A (en) 2000-10-03
BG103852A (en) 2000-06-30
BR9808720A (en) 2000-07-11
IL132570A0 (en) 2001-03-19
TNSN98059A1 (en) 2005-03-15

Similar Documents

Publication Publication Date Title
UY24989A1 (en) CARPROPHEN, A COX-2 INHIBITOR, USEFUL IN TREATING PAIN AND INFLAMMATION IN DOGS
BR0212142A (en) Method and system for acne treatment
Clancy JR et al. Achilles tendonitis in runners: a report of five cases
ES2064327T3 (en) USE OF ICAM-1 OR ITS FUNCTIONAL DERIVATIVES FOR THE TREATMENT OF NON-SPECIFIC INFLAMMATION.
CA2241981A1 (en) Method of inhibiting photoaging of skin
ATE39323T1 (en) INJECTABLE SOLUTION TO TREAT INFLAMMATION.
ATE88346T1 (en) COMPOSITION CONTAINING A NON-STEROID ANTI-INFLAMMATORY AND A NON-BACTERICIDE TETRACYCLINE.
ES2162942T3 (en) NEW DERIVATIVES OF CARBOXILIC ACIDS, THEIR OBTAINING AND EMPLOYMENT.
EA200100572A1 (en) METHOD OF APPLICATION OF CYCLOOXIGENASE-2 INHIBITOR AND ONE OR MULTIPLE ANTITUMOR MEDICINES AS A COMBINED METHOD OF MEDICAL EXPOSURE IN THE TREATMENT OF NEOPLASIA
ES2159851T3 (en) AMIDES OF AMINOTIOFENOCARBOXILIC ACIDS AND THEIR EMPLOYMENT AS INHIBITORS OF PHOSPHODIESTEARASA.
BR9406746A (en) Process compound for its preparation Pharmaceutical preparation use of process compound for obtaining inhibition of thrombin in a human organism or animal structural fragment
CY1108617T1 (en) LALPIC ACID LOCAL USE FOR HOSPITAL OR ACME TREATMENT
DE69526344D1 (en) STABILIZED COMPOSITION FOR TOPICAL TREATMENT OF SKIN DISEASES
EA200000825A1 (en) COMPOSITION INCLUDING IL-1 INHIBITOR AND POLYMER MONITORING THE LIBERATION
ATE31243T1 (en) USING 4-AMINOSALICYLIC ACID AS AN ANTI-INFLAMMATORY INGREDIENT.
EA200100721A1 (en) GABAPENTINA DERIVATIVE FOR THE PREVENTION AND TREATMENT OF VISCERAL PAIN
DE3687429D1 (en) GAMMA-IFN AS AN ACTIVE SUBSTANCE FOR INHIBITING (PREVENTING) DEGREASING PROCESSES IN THE BONE.
EA199900542A1 (en) COMPOUNDS OF SULPHONIC ACID OR SULPHONYLAMINO-N- (HETEROARALKYL) -ASAGHETHROCYCLOSYME
PT697814E (en) FORMULATIONS FOR VERTERING CONTAINING POLYMERIC MATERIAL GLICOIS AND GLYCERIDES
PT1005460E (en) BIOSSINTESE OF PROSTAGLANDINE-ENDOPEROXIDE H-SINTASE INHIBITORS
MX9304564A (en) COMBINATIONS OF MUSCLE RELAXANT-IBUPROFEN.
IT1295357B1 (en) COSMETIC FORMULATIONS USEFUL IN THE PREVENTIVE AND CURATIVE TREATMENT OF HAIR LOSS AND THEIR USE
IS5239A (en) Use of analogous gamma-aminobutyric acid (GABA) tablets to GABA-pentin for the treatment of inflammatory disease
ATE178207T1 (en) USE OF 2-(2-NITRO-4-TRIFLUORMETHYLBENZOYL)-1,3-CYCLOHEXANDIONE FOR THE TREATMENT OF TYROSINEMIA AND PHARMACEUTICAL COMPOSITIONS
CO5021216A1 (en) SELECTIVE CARPROPHENE FOR COX-2, FOR THE TREATMENT OF PAIN AND INFLAMMATION IN DOGS

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20130108